Search | Clinical Trials Finder

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 456906, Placebo, Semaglutide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 31
States / cities: Huntington Park, California • Los Angeles, California • Northridge, California + 27 more

Conditions: Hypertriglyceridemia, Cardiovascular Diseases
Interventions: ISIS 678354, Placebo; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Cottonwood, Arizona • Little Rock, Arkansas • Carmichael, California + 21 more

Conditions: Streptococcus Pneumoniae
Interventions: PG4 vaccine in Buffer 1 with low dose PA-001, PG4 in Buffer 1 with low dose PA-002, PG4 in Buffer 1 with high dose PA-001, PG4 vaccine in Buffer 1 with high dose PA-002, PG4 vaccine in Buffer 2, 20-valent pneumococcal conjugate vaccine, Saline injection; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 84 Years
Enrollment: 380 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Lake Forest, California • Rolling Hills Estates, California • Greenacres City, Florida + 13 more

Conditions: Non-Traumatic Subarachnoid Hemorrhage
Interventions: Metoprolol, Placebo; Drug
Lead sponsor: Madeleine Puissant; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Portland, Maine

Conditions: General Anesthesia
Interventions: HSK3486, Propofol, Placebo; Drug
Lead sponsor: Haisco-USA Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Malaria
Interventions: PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9%; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acromegaly
Interventions: octreotide capsules, Matching placebo; Drug
Lead sponsor: Chiasma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 19
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 13 more

Conditions: Crohn Disease
Interventions: Ustekinumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 9
States / cities: Wilmington, Delaware • Atlanta, Georgia • Rochester, Minnesota + 6 more

Conditions: Healthy Volunteers
Interventions: ABBV-141, Placebo for ABBV-141; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
Interventions: Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 41
States / cities: Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more

Conditions: Diabetes Mellitus, Type 2
Interventions: albiglutide, placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 310
States / cities: Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 250 more

Conditions: Breast Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Exemestane, Everolimus; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • New Haven, Connecticut + 12 more

Conditions: COVID-19, SARS-CoV 2
Interventions: Canakinumab Injection 600mg, Canakinumab Injection 300mg, Placebos; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Weston, Florida • Cleveland, Ohio

Conditions: Hepatorenal Syndrome
Interventions: Ifetroban Injection, Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 11
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 8 more

Conditions: Acute Gastroenteritis, Norovirus Acute Gastroenteritis
Interventions: mRNA-1403, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37,864 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 184
States / cities: Birmingham, Alabama • Cullman, Alabama • Daphne, Alabama + 136 more

Conditions: Atopic Dermatitis
Interventions: Benralizumab, Placebo / Benralizumab; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 13
States / cities: Los Angeles, California • Newport Beach, California • Bridgeport, Connecticut + 9 more

Conditions: Postsurgical Pain
Interventions: Placebo Injection, AYX1 Injection 110 mg, AYX1 Injection 330 mg; Drug
Lead sponsor: Adynxx, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 7
States / cities: Sheffield, Alabama • Phoenix, Arizona • Boynton Beach, Florida + 4 more

Conditions: Healthy
Interventions: 0.5mg AZ-010; placebo, 1mg AZ-010, 3mg AZ-010, AZ-010 1mg, IV Granisetron 1mg, Placebo; Combination Product · Drug · Other
Lead sponsor: Nova Pneuma Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Interventions: Eplontersen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 51
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 39 more

Conditions: Multiple Myeloma
Interventions: Ramantamig, Tocilizumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Goodyear, Arizona • Beverly Hills, California • Irvine, California + 2 more

Conditions: Hyperlipidemia
Interventions: Bococizumab (PF-04950615; RN316), Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2,139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 155
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 115 more

Conditions: Osteoporosis
Interventions: Teriparatide, Alendronate, Calcium, Vitamin D, Placebo-Oral, Placebo-SC; Drug · Dietary Supplement
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years to 85 Years · Female only
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 15
States / cities: Mobile, Alabama • Tustin, California • Lakewood, Colorado + 12 more

Conditions: Plaque Psoriasis
Interventions: Acitretin (also called U0279), Placebo, Etanercept; Drug · Biological
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: San Francisco, California • Louisville, Kentucky • New York, New York

Conditions: Burns
Interventions: cNP8, Placebo; Drug · Other
Lead sponsor: Neomatrix Therapeutics, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Search by objective public record fields.

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

A Study to Learn About How a New Pneumococcal Vaccine Works in Adults

Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)

Dose-Finding and Human Abuse Potential Study Of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users

First-in-Human PfSPZ-LARC2 Vaccination/CHMI

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Safety and Efficacy of Albiglutide in Type 2 Diabetes

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Canakinumab in Covid-19 Cardiac Injury (The Three C Study)

Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

Staccato® Granisetron Single Dose PK

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

The Forteo Alendronate Comparator Trial

Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis

Phase 1 Healthy Volunteer Burn Therapy Study